GLA and Fabry disease: Three FD patients in the Phase 2 clinical studies had GLA missense mutations (p.N215S, p.P205T, and p.R301Q), and had shown increased PBMC α-Gal A activity and decreased urine GL-3 levels after migalastat HCl administration [26].